Drug intelligence / Profile preview

CBT-1 + paclitaxel

Development stage: Unknown
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

CBT-1 + paclitaxel is a combination therapy consisting of CBT-1, an orally administered bisbenzylisoquinoline P-glycoprotein (Pgp/MDR1/ABCB1) inhibitor, and paclitaxel, a taxoid chemotherapeutic agent. CBT-1 works by inhibiting Pgp-mediated drug efflux, a mechanism that cancer cells often use to develop resistance to chemotherapy drugs. Paclitaxel works by damaging the structure or "skeleton" that supports cancer cells, preventing them from growing and dividing. The combination aims to overcome drug resistance in cancer cells by inhibiting the Pgp efflux pump with CBT-1, potentially allowing paclitaxel to accumulate in cancer cells at higher concentrations and improve its efficacy.

Targets

ABCB1 (P-glycoprotein)

Beyond the preview

Go deeper on CBT-1 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBT-1 + paclitaxel.

Explore the full profile